Shenzhen Kangtai Biological Products Co (SZSE:300601) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Shenzhen Kangtai Biological Products Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Shenzhen Kangtai Biological Products Co is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Shenzhen Kangtai Biological Products Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Kangtai Biological Products Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shenzhen Kangtai Biological Products Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Kangtai Biological Products Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Shenzhen Kangtai Biological Products Co's Risk Assessment falls into.

Shenzhen Kangtai Biological Products Co (SZSE:300601) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Shenzhen Kangtai Biological Products Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Shenzhen Kangtai Biological Products Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Kangtai Biological Products Co (SZSE:300601) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Kangtai Biological Products Co Ltd (SZSE:300601) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

No. 6 Kefa Road, Science and Technology Industrial Park, Nanshan District, Shenzhen, CHN, 518057

Website

http://www.biokangtai.com

Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.

Executives

Liu Jian Kai	Directors, executives
Tao Jin	Secretary Dong
Zheng Hai Fa	Directors, executives
Zhou Hui	Executives
Miao Xiang	Directors, executives
Wen Fei Dong	Director
Du Wei Min	Directors, executives
Lv Zhi Yun	Supervisors
Gan Jian Hui	Executives
Zhu Zheng Yu	Executives
Liu Qun	Executives
Li Tong	Executives
Yuan Li Ping	Director
Li Xiang Ming	Independent director

Shenzhen Kangtai Biological Products Co (SZSE:300601) Headlines

No Headlines